Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study

Treating advanced or recurrent melanoma remains a challenge. Cancer cells can evade the immune system by blocking T‐cell activation through overexpression of the inhibitory receptor programmed death 1 (PD‐1) ligands. The PD‐1 inhibitor nivolumab blocks the inhibitory signal in T cells, thus overcomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Naoya, Kiyohara, Yoshio, Uhara, Hisashi, Uehara, Jiro, Fujimoto, Manabu, Takenouchi, Tatsuya, Otsuka, Masaki, Uchi, Hiroshi, Ihn, Hironobu, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480079/
https://www.ncbi.nlm.nih.gov/pubmed/28342215
http://dx.doi.org/10.1111/cas.13241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480079/
https://www.ncbi.nlm.nih.gov/pubmed/28342215
http://dx.doi.org/10.1111/cas.13241

Ejemplares similares